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Purpose: This study investigated the effect of dual bronchodilation with the long-acting 
β-receptor agonist/long-acting muscarinic antagonist combination, indacaterol/glycopyrronium 
(IND/GLY), on nighttime oxygenation, lung function, sleep quality, and symptoms in patients 
with moderate-to-severe COPD.
Patients and methods: This was a 4-week, double-blind, multicenter, placebo-controlled, two-
period crossover study. Patients were randomized in a 1:1 ratio to receive IND/GLY 110/50 µg 
once daily or matching placebo. The primary objective was to evaluate the effect of treatment 
with IND/GLY on mean nighttime oxygenation, compared with placebo. The secondary objec-
tive was to determine the time spent ,90% in blood oxygen saturation (SpO
2
) compared with 
placebo. Exploratory objectives were to assess the effect of IND/GLY, compared with placebo, 
on sleep quality measured by the Medical Outcomes Study (MOS) Sleep Scale and the COPD 
and Asthma Sleep Impact Scale (CASIS) questionnaires and on symptoms assessed by COPD 
Assessment Test (CAT) questionnaire.
Results: In total, 38 patients were randomized (n=22, IND/GLY; n=16, placebo). The change 
in nighttime oxygenation (SpO
2
) was similar, and there was a comparable difference in time 
spent ,90% SpO
2
 between IND/GLY and placebo. Increases from baseline for the difference 
between IND/GLY and placebo for trough FEV
1
, FVC, and inspiratory capacity (P,0.05) 
were seen, with a corresponding reduction in residual volume and functional residual capacity 
(P,0.05). IND/GLY treatment showed an improvement in scores for CAT (P=0.0208), 
CASIS, and the MOS Sleep Scale measures, Sleep Problems Index I, Sleep Problems Index II 
(P=0.0315), Sleep Adequacy, Sleep Disturbance Scale, Somnolence Scale, and Short of Breath 
Scale (P=0.0031).
Conclusion: In this study, IND/GLY 110/50 µg once daily improved symptoms, sleep quality, 
and lung function, but showed no effect on nighttime oxygenation in patients with moderate-
to-severe COPD.
Keywords: bronchodilator, sleep, hypoxia, quality of life, lung function
Introduction
Sleep disturbances and nighttime symptoms are frequently experienced by patients 
with respiratory diseases.1–3 Patients with COPD report poorer quality of sleep than 
those of a similar age without COPD.4 While epidemiological studies suggest that at 
least 75% of patients with COPD experience nocturnal symptoms and symptomatic 
sleep disturbance, physicians are often unaware of these, because they go unreported 
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by patients.5 In a recent survey, 61% of patients with COPD 
reported both nighttime and early morning symptoms, most 
frequently coughing, wheezing, and shortness of breath. 
Of those with nighttime symptoms, 77.7% reported slight-
to-extreme sleep disturbances, 34.4% reported awakening at 
least once each night, and 25.3% reported difficulty falling 
asleep.6 More than 50% of patients in the Subpopulations 
and Intermediate Outcome Measures in COPD Study, a large 
COPD cohort study, reported poor sleep quality, and sleep 
quality was a significant predictor of the quality of life.7,8
When patients with COPD experience hypoxia during the 
night, it frequently appears as prolonged oxygen desatura-
tions during rapid eye movement (REM) sleep.9 Nighttime 
hypoxia may be a problem even in patients without signifi-
cant daytime hypoxia.10 Several mechanisms including gas 
exchange alterations, lung volume alterations, reduced respi-
ratory effort, and ventilation–perfusion (V/Q) mismatch are 
involved in sleep-related breathing disorders and hypoxemia 
in patients with COPD.11
Progressive airflow limitation and destruction of the 
pulmonary capillary bed in patients with COPD result in 
V/Q mismatch.2 The reduction in functional residual capacity 
(FRC) which occurs during sleep, as well as the reported 
10% decrease in FRC associated with a supine position, may 
add to V/Q mismatch in patients with COPD,12,13 leading to 
lower oxygen reserves.3 Decreased mucociliary clearance in 
patients with COPD while sleeping may cause worsening of 
V/Q mismatch.3 The progression of COPD to its end stages 
of severe hypoxemia, right heart failure, and death may 
be dependent upon the severity of desaturation occurring 
during sleep.14–17
Patients treated with the long-acting muscarinic antago-
nist (LAMA) tiotropium showed significant improvements 
in sleep arterial oxygen saturation (SaO
2
) compared with 
placebo, especially during REM sleep. However, there 
was no improvement in sleep quality, measured by either 
polysomnography or patients’ subjective perception, or 
daytime sleepiness assessed by the Epworth Sleepiness Scale 
(ESS) score.18 A study of the long-acting β-receptor agonist 
(LABA) salmeterol showed similar results: SaO
2
 and the 
percentage of sleep spent ,90% in oxygenation improved 
significantly in patients with COPD treated with salmeterol, 
compared with placebo; however, there was no concomitant 
improvement in sleep quality.19
Dual bronchodilation with the fixed LABA/LAMA 
combination indacaterol/glycopyrronium (IND/GLY) improves 
lung function and reduces exacerbations more than either of its 
components, or open-label tiotropium,20,21 or the combination 
of salmeterol and fluticasone in patients with COPD.22,23 Given 
that a considerable degree of symptoms, including potential 
hypoxemia, in COPD may be confined to the sleeping period, 
it was hypothesized that induction of optimal dual broncho-
dilation would increase nocturnal oxygenation and improve 
sleep quality and COPD symptoms. The aim of this study 
was to investigate the effect of IND/GLY 110/50 µg once 
daily on nighttime oxygenation, lung function, sleep quality, 
and symptoms in patients with moderate-to-severe COPD.
Patients and methods
study design
This was a randomized, double-blind, multicenter, placebo-
controlled, two-period crossover study (Figure 1). From 
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Indacaterol/glycopyrronium: nighttime oxygenation and symptoms
November 2014 through June 2016, patients were enrolled at 
five sites across Norway, Sweden, and Denmark. Each screen-
ing visit was followed by a run-in period of up to 14 days, 
dependent on COPD therapy, before randomization.
Patients were randomized in a 1:1 ratio to initially receive 
IND/GLY 110/50 µg (Novartis Pharma AG, Basel, Switzer-
land) once daily or matching placebo. Both treatment periods 
were of 4 weeks’ duration, with a 2-week washout period in 
between. Patients took their usual short-acting β
2
-agonists 
(SABA) as rescue medication on an “as-needed” basis 
throughout the study. Patients who were being treated with 
an inhaled corticosteroid (ICS) plus an LABA discontinued 
this treatment and were instead prescribed ICS monotherapy 
at an equivalent dose and dosing regimen for the duration 
of the study.
The trial was approved by the Independent Ethics 
Committee at each trial site. The study was registered at 
ClinicalTrials.gov (Identifier Number: NCT02233543) and 
was conducted according to the ethical principles of the 
Declaration of Helsinki. Informed consent was obtained 
from each patient in writing before conducting any study-
specific procedures.
Participants
The study enrolled patients aged $40 years, with resting 
daytime oxygen saturation (SpO
2
), as measured by pulse 
oximetry, of #95%, a post-bronchodilator FEV
1
 $30% 
and ,60% of the predicted normal value, and a clinical 
diagnosis of COPD (according to the GOLD 2014) with a 
post-bronchodilator FEV
1
/FVC ,0.70. All the participants 
were current or ex-smokers who had a smoking history of 
at least 10 pack-years. Significant sleep apnea, defined as an 
Apnea–Hypopnea Index of $15 events/hour, constituted an 
exclusion criterion. Full details of inclusion and exclusion 
criteria are listed in the Supplementary materials.
Objectives and efficacy assessments
The primary objective of this study was to evaluate the effect 
of 4 weeks of treatment with IND/GLY on mean nighttime 
oxygenation in patients with moderate-to-severe COPD com-
pared with placebo. The secondary objective was to determine 
the time spent at ,90% in blood oxygen saturation (SpO
2
) 
compared with placebo in these patients. One exploratory 
objective was to assess the lung function and lung volumes 
after 4 weeks’ administration of IND/GLY, compared with 
placebo, measured in the morning prior to drug administra-
tion using plethysmography and diffusing capacity of the 





), FVC, total lung capacity, FRC, residual volume, 
inspiratory capacity (IC), DLCO, and DLCO divided by the 
volume of the alveolar (DLCO/VA). A second exploratory 
objective was to assess the effect of IND/GLY, compared 
with placebo, on sleep quality measured by the Medical 
Outcomes Study (MOS) Sleep Scale24 and the COPD and 
Asthma Sleep Impact Scale (CASIS) questionnaires7 and 




) was measured using respi-
ratory polygraphy at home over two consecutive nights prior 
to visits 2, 3, 4, and 5. All the patients used an Embletta® 
(Stowood, Oxford, UK) or NOX-T3® (Nox Medical, 
Reykjavík, Iceland) polygraph for the measurement of SpO
2
 
at night. Data collected during the polygraphy recording 
were stored in a computer and subsequently transferred to a 
database for a centralized analysis procedure. The polygraphy 
expert, who was blinded for patient information, documented 
the SpO
2
 results in the electronic case report forms (eCRFs). 
To support the evaluation of the polygraph data, the patients 
recorded information in a night report, including bedtime and 
wake-up time, the number of times the patient had left the bed 
during the night, and the use of rescue medication. Time 
spent in an upright position and time reported as awake time 
by the patient were excluded from the polygraph analyses. 
Data from the second night were applied in the analyses (to 
avoid a “first night effect”) if judged as technically accept-
able by the sleep technician, who was blinded for the patient 
treatment randomization. Time spent ,90% in SpO
2
 was 
calculated based on the SpO
2
 data recorded by polygraphy 
during the night.
Body plethysmography and DLCO measurements were 
taken according to the recommendations of the American 
Thoracic Society/European Respiratory Society Task Force 
on standardization of lung function testing, using the 
spirometric prediction equation standards for the European 
Community for Coal and Steel.26,27 At sites where plethys-
mography was performed, the patients were instructed to 
withhold the use of SABA (rescue medication) for at least 
6 hours before all clinic visits, unless the use was absolutely 
necessary. Furthermore, the patients at these sites were asked 
to take study drugs in the morning between 08:00 and 09:00 
on the day before clinic visits, to ensure that at least 24 hours 
had passed from last study drug intake to plethysmography 
measurements.
The patients completed the MOS Sleep Scale (a self-
administered questionnaire with 12 questions on different 
dimensions of sleep), CASIS (a patient-reported measure 
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and CAT questionnaire (a short instrument used to quantify 
the symptom burden of COPD and assess the health status 
of patients) before any study-related procedures were con-
ducted at visits 2, 3, 4, and 5. One experienced sleep techni-
cian scored the sleep recordings from all sites throughout 
the study.
safety assessments
Safety assessments consisted of collecting all adverse events 
(AEs), serious AEs (SAEs), with their severity and relation-
ship to study drug, and pregnancies. All AEs were recorded 
using an eCRF for all patients included in the safety analysis.
statistical analysis
The safety set population consisted of patients who received 
at least one dose of one of the study treatments. The full 
analysis set (FAS) population consisted of patients who 
were included in the safety set population and had at least 
one assessment of the primary and/or secondary efficacy 
variables.
Patient demographics and baseline characteristics were 
presented using summary statistics. Preplanned, statisti-
cal hypothesis tests were performed for the primary and 
secondary objectives, nighttime oxygenation, and time 
spent ,90% in SpO
2
 after 4 weeks of treatment, while other 
exploratory endpoints were generally presented using sum-
mary statistics.
Post hoc analyses were carried out for the exploratory 
variables: lung function analyses, MOS Sleep Scale, CASIS, 
and CAT. The treatment comparisons between IND/GLY 
and placebo were analyzed by mixed model with period and 
treatment as fixed effects, baseline as a covariate effect, and 
subject as a random effect. Based on this model, two-sided 
tests were performed using a 5% level of significance, and a 
95% two-sided CI for the estimated difference in least square 
means was presented. The exploratory variable Optimal 
Sleep Scale (part of the MOS Sleep Scale) was analyzed by 
binomial model including period, baseline, and actual treat-
ment as fixed effects and patient as a random effect.
A post hoc logistic regression analysis was carried out 
for change in SpO
2














 $2 vs #−2) during treatment periods. The following 
were covariates in the analysis: age, body mass index, daytime 
oxygen saturation, DLCO, DLCO/VA; FEV
1
% of predicted 
normal, FEV
1
, sex; and total CAT score. The last available 
measurements before the first treatment were used for each 
covariate. The model included baseline SpO
2
, treatment 
period, the relevant covariate, and its corresponding interac-
tion with treatment, with the patient as a random effect.
sample size calculation
For the crossover design, a paired t-test was used for the 
sample size calculation with a mean difference of 2, SD 
of 3.8, and a significance level of 0.05. A Δ of 2 (change 
in nighttime oxygenation in percent) was chosen, based 
upon the effect seen with long-acting bronchodilators in 
monotherapy. With a correlation coefficient of 0.3 or 0.6, 
the number of patients needed to ensure 80% power would 
have been 42 or 26, respectively. With a Δ of 2, 26 of 
50 patients would have been needed to complete the study to 
maintain 80% power (equal to a dropout rate of 48%). Thus, 
with 50 patients included, it was expected that a sufficient 
number of patients would complete the trial to allow credible 
statistical analyses of the data collected.
Results
study participants
In total, 71 patients were screened. During the run-in period, 
5 patients discontinued the study and 38 patients were ran-
domized initially to receive IND/GLY or placebo (n=22 IND/
GLY; n=16 placebo). Both the FAS population and safety set 
consisted of 38 patients. Figure 2 shows the reasons for discon-
tinuation during the screening, run-in, and treatment periods.
Patient demographics and baseline characteristics were 
balanced between the two treatment groups (Table 1). The 
mean age in the safety population was 68.4 years with a range 
of 55–81 years. Twenty-one patients were diagnosed with 
COPD before 2010. Approximately 66% of patients did not 
experience an exacerbation during the previous 12 months. 
The SpO
2
 at baseline for all the patients was #95% as defined 
by the inclusion criterion; the lowest result reported was 
89% (n=1), and the highest was 95% (n=12).
Efficacy outcomes
The primary efficacy analysis showed that the change in 
nighttime oxygenation (SpO
2
) was similar (P=0.2419) 
between IND/GLY and placebo after 4 weeks of treatment 
for the FAS population (Table 2; Figure 3). A high degree 
of interindividual variability was seen (Figure 3). Likewise, 
the secondary analysis also showed a comparable difference 
in time spent ,90% in SpO
2
 between IND/GLY and placebo 
(P=0.2016). The logistic regression analysis showed that 
none of the covariates evaluated were significantly associated 
with the change from baseline in SpO
2
 at any of the cutoff 
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Indacaterol/glycopyrronium: nighttime oxygenation and symptoms
The analysis of lung function parameters showed posi-
tive changes from baseline for the difference between IND/
GLY and placebo for tFEV
1
, FVC, and IC (P,0.05) and a 
corresponding negative change in residual volume and FRC 
(P,0.05; Table 3). No differences were seen in diffusion 
capacity between IND/GLY and placebo treatment.
After 4 weeks of treatment, there was an improvement 
in mean (SD) CAT total score from baseline for IND/GLY 
(−1.5 [3.5]; negative score indicates improvement), while the 
change was positive for placebo (1.2 [5.2]; ie, disimprove-
ment). The treatment difference in change from baseline 
mean (SD) was −3.1 (6.5). Least squares (LS) means analysis 
showed a treatment difference of −2.56 (−4.72, −0.40), 
P=0.0208 in favor of IND/GLY (Table 4).
Mean (SD) CASIS total score slightly improved from 
baseline for both treatments (−0.2 [2.5] for IND/GLY 
and −0.2 [2.7] for placebo; negative score indicates improve-

















Figure 2 Trial profile.
Notes: *One patient was randomized to receive Ing/glY in Period 1, but received placebo in error. The patient received placebo for one week in Period 2 and then InD/
glY for four weeks.
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significant (−0.4 [2.8], LS means −0.02 [−1.03, 1.00], 
P=0.9724; Table 4).
For the MOS Sleep Scale, there was an improvement 
from baseline mean (SD) total score for IND/GLY for 
the following sleep scale scores (negative score indicates 
improvement): Sleep Problems Index I (−3.55 [11.25]), Sleep 
Problems Index II (−3.17 [9.14]), Sleep Disturbance Scale 
(−2.39 [10.85]), Sleep Quantity (−0.05 [0.68]), Somnolence 
Scale (−1.29 [14.75]), and Short of Breath Scale (−6.45 
[14.04]). For placebo, an improvement was seen for Sleep 
Problem Index I (−0.11 [8.42]), Sleep Quantity −0.08 [0.51], 
and Snoring scale 0.71 [19.23]. LS means analysis showed 
that the treatment differences were significant for Sleep 
Problems Index II and Short of Breath scale (Table 4).
safety outcomes
Forty-one AEs were reported, of which 24 were for IND/GLY 
treatment and 17 for placebo. Twelve AEs were assessed as 
related to either the investigational or other treatment: five 
for IND/GLY treatment and seven for placebo treatment. 







age (years) 68.0 (7.3) 69.0 (4.6) 68.4 (6.2)
Male sex, n (%) 14 (63.6) 10 (62.5) 24 (63.2)
BMI (kg/m2) 25.5 (3.5) 24.6 (4.2) 25.1 (3.8)










Total pack-years 42.9 (26.7) 34.6 (13.3) 39.4 (22.2)
FeV1 (l) 1.44 (0.42) 1.21 (0.25) 1.34 (0.37)
FeV1 % of predicted normal (%) 47.83 (7.01) 44.94 (7.73) 46.61 (7.36)
FVC (l) 3.20 (0.94) 3.15 (0.77) 3.18 (0.86)
FeV1/FVC 0.46 (0.07) 0.40 (0.09) 0.43 (0.08)
Daytime saO2 (%) 90.4 (20.6) 88.4 (23.4) 89.5 (21.5)
PaO2 (kPa) 9.6 (1.5) 9.3 (1.0) 9.5 (1.3)
hCO3 (mmol/l) 25.6 (1.7) 24.2 (6.1) 25.0 (4.2)
Note: Values are mean ± SD unless specified.
Abbreviations: BMI, body mass index; hCO3, bicarbonate in blood; InD/glY, indacaterol/glycopyrronium; PaO2, partial pressure of oxygen in arterial blood; saO2, oxygen 
saturation.
















nighttime (mean ± sD) oxygenation spO2
Baseline (visit 2 or 4) 89.73±2.08 89.87±1.70 – – – –
Posttreatment (visit 3 or 5) 89.61±2.12 89.97±2.02 89.59±0.30 90.04±0.28 – –
Treatment difference – – – – −0.44 (−1.21, 0.32) 0.2419
Time (% ± sD) spent ,90% in spO2
Baseline (visit 2 or 4) 43.48±37.21 38.81±32.74 – – – –
Posttreatment (visit 3 or 5) 43.75±35.26 37.59±31.45 44.37±5.09 36.58±4.84 – –
Treatment difference – – – – 7.79 (−4.51, 20.08) 0.2016
Notes:  LS-means analysis was carried out using a mixed Model including period and actual treatment as fixed effects, baseline as covariate and subject effect as random. 
aOnly includes patients with data from both treatments.
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Indacaterol/glycopyrronium: nighttime oxygenation and symptoms
The most frequently reported AEs were dyspnea, deteriora-
tion in COPD, nasopharyngitis, oropharyngeal pain, and 
increase in blood glucose (Table S1).
Most AEs for both treatments were mild or moderate in 
intensity; further details are available in the Supplementary 
materials. Three AEs were classified as SAEs: one patient 
treated with IND/GLY who experienced two individual SAEs 
(acute respiratory failure and severe COPD exacerbation) 
discontinued the study; the second patient (treated with 
placebo) had a COPD exacerbation, which was not believed 
to be related to the study drug, but the patient discontinued. 
No patients died during the study.
Discussion
To our knowledge, this is the first study to investigate the 


















Figure 3 Mean nighttime blood oxygen saturation (spO2) using respiratory polygraphy (full analysis set) at baseline and week 4.
Abbreviation: InD/glY, indacaterol/glycopyrronium.
Table 3 analysis of lung function parameters
Lung function parameters IND/GLY (N=35) Placebo (N=34) Difference IND/GLY–placebo
LS means (SE) LS means (SE) Estimate (95% CI) P-value
tFeV1 (l) 1.33 (0.04) 1.14 (0.05) 0.19 (0.08, 0.29) 0.0021
FrC (l) 4.53 (0.15) 5.09 (0.15) −0.56 (−0.99, −0.12) 0.0141
FVC (l) 3.17 (0.12) 2.60 (0.13) 0.57 (0.23, 0.91) 0.0025
IC (l) 2.37 (0.07) 2.07 (0.07) 0.31 (0.13, 0.49) 0.0022
rV (l) 3.59 (0.15) 4.22 (0.15) −0.63 (−1.06, −0.20) 0.0049
TlC (l) 6.91 (0.13) 7.15 (0.14) −0.25 (−0.64, 0.14) 0.2001
DlCOa (mmol/kPa × min) 4.89 (0.37) 4.65 (0.37) 0.24 (−0.14, 0.62) 0.1883
DlCO/Vaa (mmol/kPa × min/l) 0.94 (0.05) 0.90 (0.06) 0.03 (−0.04, 0.11) 0.3248
Note: aOnly measured in patients at Denmark and norway sites.
Abbreviations: DlCO, diffusing capacity of the lung for carbon monoxide; DlCO/Va, DlCO divided by the alveolar volume; tFeV1, trough FeV1; FrC, functional residual 
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and sleep quality in patients with COPD. Sleep quality 
assessed by the CASIS score and the MOS Sleep Scale 
improved after 4 weeks of treatment with IND/GLY. Two 
measures of the MOS Sleep Scale showed significant dif-
ferences compared with placebo, as did the CAT score and 
lung function parameters. However, there was no difference 
in the primary objective, improvement in mean nighttime 
SpO
2
 after 4 weeks of IND/GLY treatment compared with 
placebo, or the secondary objective, improvement in time 
spent ,90% in SpO
2
. A high degree of interindividual vari-
ability was seen and we identified individual patients whose 
overnight oxygenation improved significantly during IND/ 
GLY treatment; we cannot exclude that this responder pattern 
corresponds to a specific COPD phenotype.
Patients treated with IND/GLY showed an improvement 
in scores for CAT, CASIS, and the MOS Sleep Scale mea-
sures, Sleep Problems Index I, Sleep Problems Index II, Sleep 
Adequacy, Sleep Disturbance Scale, Somnolence Scale, and 
Short of Breath Scale. The findings were significantly dif-
ferent to placebo for CAT score, Sleep Problems Index II, 
and Short of Breath Scale. Neither of the previous studies 
of the effect of bronchodilation on sleep quality showed 
similar improvements in sleep quality by the measures used 
in those studies.18,19 In the tiotropium study, sleep quality 
was assessed by polysomnography, information from the 
patient diary, and sleepiness by the ESS, with no significant 
difference to placebo for any measure.18 In the salmeterol 
study, sleep quality was measured using polysomnography 
and sleepiness by the ESS; similarly to the tiotropium study, 
there was no difference between the active treatment and 
placebo.19 Treatment with IND/GLY significantly improved 
lung function parameters, indicating both bronchodilatory 
effects and a reduction of hyperinflation. These findings 
are consistent with previously reported positive effects of 
IND/GLY on lung function.20–22
Past studies of bronchodilators in COPD showed a posi-
tive effect on nighttime oxygenation. Patients treated with 
the LAMA, tiotropium, showed significant improvements in 
sleeping arterial SaO
2
 compared with placebo, with tiotro-
pium in particular during REM sleep.18 Similarly, patients 
treated with the LABA, salmeterol, showed an improve-
ment in both SaO
2
 and the percentage of sleep spent ,90% 
in patients with COPD compared with placebo.19 There 
are some possible explanations for the difference between 
our results and those reported previously.18,19 Unlike pre-
vious studies, our study used respiratory polygraphy, 
Table 4 ls means and difference in ls means for symptoms and sleep quality measures after 4 weeks of treatment with InD/glY 
or placebo
Symptoms and sleep quality 
measures









Total CaT score 15.15±0.75 17.71±0.77 −2.56 (−4.72, −0.40) 0.0208
CasIs
Total CasIs score 15.29±0.47 15.31±0.48 −0.02 (−1.03, 1.00) 0.9724
MOs sleep scale
sleep Problems Index I 21.36 (1.66) 24.41 (1.66) −3.05 (−7.76, 1.67) 0.2006
sleep Problems Index II 22.42 (1.35) 26.63 (1.39) −4.21 (−8.02, −0.40) 0.0315
sleep adequacy 68.78 (3.44) 69.17 (3.44) −0.39 (−10.27, 9.49) 0.9358
sleep Disturbance scale 22.96 (1.69) 27.33 (1.75) −4.37 (−9.07, 0.33) 0.0672
sleep Quantity (raw score) 6.61 (0.11) 6.58 (0.11) 0.03 (−0.28, 0.34) 0.8302
somnolence scale 25.07 (2.24) 26.71 (2.24) −1.64 (−8.00, 4.73) 0.6088
snoring scale 33.26 (3.48) 31.50 (3.42) 1.76 (−8.12, 11.65) 0.7218
short of Breath scale 4.91 (2.02) 13.76 (2.02) −8.85 (−14.59, −3.11) 0.0031
OR (IND/GLY/placebo)
Estimated odds Estimated odds Estimate P-value
Optimal sleep scale 1.07 1.02 7.79 (−4.51, 20.08) 0.2016
Notes: The MOS Sleep Scale, CASIS, and CAT were analyzed according to the mixed model presented with period and treatment as fixed effects, baseline as a covariate 
effect, and patient as a random effect. The Optimal sleep scale (part of the MOs sleep scale) was analyzed by a binomial model including period, baseline and actual treatment 
as fixed effects and patient as a random effect. Values are mean ± SE unless specified otherwise. aOnly includes patients with data from both treatments.
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Indacaterol/glycopyrronium: nighttime oxygenation and symptoms
not polysomnography. Sleep induces alterations in gas 
exchange with the normal ventilatory response to hypoxia 
and hypercapnia being reduced in those who are asleep, 
compared with those who are awake.11 The patients in our 
study may have had less total sleep time during the placebo 
period, compared with the active treatment period; this is 
supported by the reporting of more nighttime symptoms 
with placebo and worse lung function, compared with active 
treatment. If this is the case, the hypoxemia occurring during 
sleep in subjects receiving placebo could be underscored by 
a time dilution factor, by using both true sleep and periods 
of unnoticed wakefulness as the denominator. This suggests 
that the gas exchange in patients being treated with placebo 
is likely to have been similar to the active treatment, because 
humans breathe more when they are awake. We speculate 
that the lack of improvement in oxygenation corresponding 
to the improvement in lung function with active treatment 
may be related to the selection criteria for the patient group 
and/or to the relative proportions of wake and sleep time. 
Unfortunately, respiratory polygraphy does not provide 
details on sleep architecture, and it is therefore not possible to 
exclude periods of wakefulness not reported actively from the 
participants. A second factor which may have influenced our 
results is differences in COPD severity of our patient cohort 
compared with those reported previously. In our study, the 
mean FEV
1
 was 1.34 L, whereas mean FEV
1
 was 0.84 L in 
the tiotropium study18 and median FEV
1
 was 0.91 L in the 
salmeterol study.19 We hypothesize that the use of the dual 
bronchodilator in the milder COPD patients included in our 
small study, who might also have milder sleep impairment, 
may have limited the possibility of reaching a significant 
improvement in overnight oxygenation.
Strengths of our study include the randomized controlled 
trial design with rigorous measurement of nighttime oxygen-
ation, which took place over two consecutive nights at the 
beginning and end of each treatment period with a washout 
period in between. Furthermore, the same trained polygraphy 
expert, who was blinded to patient information, documented 
the SpO
2
 results for each patient. Furthermore, we used 
well-validated tools for the measurement of symptoms and 
sleep quality.7,28,29 A crossover design, rather than parallel 
group, was chosen for this study because it was expected 
that within-patient variability for the parameters assessed 
in this study would be less than between-patient variability, 
allowing the required power to be achieved while exposing 
a smaller number of patients to study treatment. The final 
analysis set consisted of 38 patients which was greater than 
that estimated to maintain 80% power (n=26).
A limitation of the study design may be the use of 
respiratory polygraphy instead of polysomnography. How-
ever, polygraphy can be performed at home in the natural 
environment, instead of overnight hospitalization. Fur-
thermore, it should be noted also that the previous studies 
using polysomnography did not detect any differences in 
sleep quality. A further limitation is that a large number of 
patients had high oxygenation saturation; however, this was 
addressed in a post hoc analysis and found not to change the 
interpretation of the data. Furthermore, selecting patients with 
moderate-to-severe COPD with mild resting hypoxemia may 
limit the generalization of the results of the study.
Conclusion
In conclusion, our study has shown that IND/GLY improves 
symptoms and sleep quality and confirms previous findings 
with regard to improvement in lung function. Contrary to our 
hypothesis, IND/GLY had no effect on nighttime oxygen-
ation which – at least in part – may be explained by the lack 
of control for actual sleep time in polygraphic recordings. 
Therefore, our recommendation is that polysomnography 
should be considered in future studies to clarify further the 
benefits of bronchodilators on sleep-related oxygenation in 
patients with moderate-to-severe COPD.
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exclusion and inclusion criteria
Patients eligible for inclusion in the study fulfilled all of the 
following criteria:
•	 Written informed consent obtained before any assessment 
was carried out;
•	 Male or female adults aged $40 years;
•	 Resting daytime oxygen saturation levels measured by 
pulse oximetry of #95% blood oxygen saturation (SpO
2
);
•	 Patients with a post-bronchodilator FEV
1
 $30% 
and ,60% of the predicted normal value;
•	 Clinical diagnosis of COPD (according to GOLD 




•	 Current or ex-smokers who have a smoking history of 
at least 10 pack-years (10 pack-years are defined as 
20 cigarettes a day for 10 years, or 10 cigarettes a day 
for 20 years).
		 Patients fulfilling any of the following criteria were not 
eligible for the inclusion in the study:
•	 Women of childbearing potential not using contraception 
method(s), as well as women who were breastfeeding;
•	 Ongoing/planned rehabilitation during the study period;
•	 An exacerbation of COPD (treatment with oral or par-
enteral antibiotics and/or glucocorticosteroids and/or 
hospitalization related to COPD) within 4 weeks before 
screening or during the run-in period;
•	 Use of oral or systemic glucocorticosteroids within 
4 weeks before screening or during the run-in period;
•	 Three or more awakenings during the night leading to 
toilet visit or other reasons for exiting the bed during 
the last week before the screening visit for non-COPD 
reasons (morning toilet visit not included);
•	 Respiratory tract infection in the 4 weeks before screening 
or during the run-in period;
•	 Body mass index .32;
•	 Diagnosed asthma;
•	 Malignancy of any organ system (except localized basal 
cell carcinoma of the skin);
•	 Diabetes mellitus requiring insulin;
•	 Long QT syndrome or QTc .450 ms (males) or 470 ms 
(females);
•	 Severe renal impairment (glomerular filtration rate: #30 mL/ 
min/1.73 m2);
•	 Patients receiving regular long-term oxygen therapy;
•	 Known sleep apnea ($15 apneas or hypopneas per hour of 
sleep) or who have or have had previous bilevel positive 
airway pressure or continuous positive airway pressure 
therapy for sleep apnea;
•	 Symptomatic urinary outflow obstruction;
•	 Shift workers (or other external conditions affecting sleep 
and sleep quality on a regular basis);
•	 Narrow-angle glaucoma;
•	 Hypersensitivity to any of the ingredients of the investi-
gational therapy;
•	 Unstable (based upon the investigator evaluation) car-
diovascular disease;
•	 Use of nonselective β-blockers, including eye drops (cau-
tious use of cardio selective β-blocking agents is allowed 
at the discretion of the investigator); and




Table S1 Most frequently reported aes (at least 1% incidence; 
safety set)
Adverse events IND/GLY (N=35) Placebo (N=34)
Patients with at least one ae 14 (40.0%) 13 (38.2%)
Dyspnea 5 (14.3%) 5 4 (11.8%) 4
COPD exacerbations 3 (8.6%) 3 4 (11.8%) 4
nasopharyngitis 3 (8.6%) 3 2 (5.9%) 2
Oropharyngeal pain 2 (5.7%) 2 –
Fatigue 1 (2.9%) 1 1 (2.9%) 1
acute respiratory failure 1 (2.9%) 1 –
Cough 1 (2.9%) 1 –
laryngospasm 1 (2.9%) 1 –
Productive cough 1 (2.9%) 1 –
local swelling 1 (2.9%) 1 –
Pyrexia 1 (2.9%) 1 –
arrhythmia 1 (2.9%) 1 –
Transient blindness 1 (2.9%) 1 –
Paresthesia 1 (2.9%) 1 –
rash 1 (2.9%) 1 –
Increased blood glucose – 2 (5.9%) 2
Pulmonary embolism – 1 (2.9%) 1
rhinorrhea – 1 (2.9%) 1
Bronchitis – 1 (2.9%) 1
reactive arthritis – 1 (2.9%) 1
Notes: x (xx.x%) y = the number of patients (the percent of patients with at least 
one ae) actual number of aes. aes are presented in descending order of frequency 
in the InD/glY group.
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Intensity of adverse events
While most adverse events were mild to moderate in inten-
sity, five severe AEs were reported. Two patients treated with 
IND/GLY reported three severe AEs: acute respiratory failure 
and COPD exacerbation, both assessed as related to the study 
drug; and transient blindness, assessed as not related. Two 
patients reported one severe AE each while being treated with 
placebo (both COPD exacerbations: one assessed as related 
to the study drug, and the other not related).
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